Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer
October 26th 2017Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).
Read More
Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval
June 21st 2017Leena Gandhi, MD, PhD, associate professor, Department of Medicine, director, Thoracic Medical Oncology Program, discusses the findings of cohort G of the KEYNOTE-021 trial that explored the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed for patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
Read More
Dr. Gandhi on Sequencing and Emerging Agents in ALK+ NSCLC
April 19th 2017Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses sequencing challenges as well as emerging agents in the field of ALK-positive non–small cell lung cancer (NSCLC).
Read More